Exploratory study to elucidate the significance of biomarker measurement by liquid biopsy over time in patients with hepatobiliary and pancreatic malignancies during systemic therapy
Not Applicable
Recruiting
- Conditions
- Hepato-biliary pancreatic malignant tumor
- Registration Number
- JPRN-UMIN000050100
- Lead Sponsor
- Fujita Health University hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 1000
Inclusion Criteria
Not provided
Exclusion Criteria
1. Patients with serious complications 2. Patients who are judged by the investigator to be ineligible for the safe conduct of this study
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The relationship between blood ctDNA profile over time and anti-tumor response
- Secondary Outcome Measures
Name Time Method The relationship between the treatment outcome and CTCs, miRNAs, tumor markers, cancer immune-related factors, and intestinal microbiota obtained from liquid biopsies (blood, urine, saliva, and stool samples) other than ctDNA.